Developing novel treatments for mental health via psychedelic therapies...
Woke Pharmaceuticals is on a mission to change the status quo in the treatment of mental health.
Woke is focused on working with leading universities and research institutes to develop psychedelic therapies to help those who struggle with mental health.
Sign up to receive the latest announcements on Woke Pharmaceuticals....
We are committed to Innovation
In addition to developing proprietary synthetic psilocybin formulations, we are pioneering novel drug discovery.
To improve patients' psychedelic experience, we are developing dosing and delivery methods for psychedelics.
The company is pursuing global patents at every opportunity, with a foundational provisional patent application already filed and many more on the way.
Latest Announcements
12.03.24
Press Release
UNIVERSITY OF WESTERN AUSTRALIA DISCOVERS NEW LSD COMPOUNDS
Initial focus on psilocybin for depression based on evidence of efficacy. Proprietary formulations to enhance release profile of active drug and secure Intellectual Property
WP001Psilocybin (low dose)Rapid release CapsuleModerate DepressionEthics approval received for Phase IIB trialMacquarie University
WP002Psilocybin (high dose)Rapid release TabletTreatment-Resistent DepressionEthics approval received for Phase IIB trialImperial College London
Drug Science (UK)
Swinburne University
WP002Psilocybin (high dose)Rapid release TabletAlcohol use disorderEthics approval received for Phase IIB trialUniversity of Sydney
WP002Psilocybin (high dose)Rapid release TabletProlonged griefEthics submission for Phase II feasibility trial in progressQIMR-Berghofer
WP002Psilocybin (high dose)Rapid release tabletChronic musculoskeletal painEthics submission for Phase II trial in Q2 CY2023Curtin University
WP003LSD (novel analogue)EnhancedAnxiety, Substance Abuse, PTSDDrug discovery – in-vitro data H1 CY2023University of Western Australia
Partnerships with leading clinicians and formulation experts
The Market | Unmet Medical Need Continues to Grow
Over 700 million people are affected globally with some sort of mental illness, eg: depression, anxiety, PTSD, addiction or eating disorder
Source: The World Health Organisation
Global economic costs due to mental heath disorders estimated to be USD$800 Billion direct and US$1.7 Billion indirect
Source: National Centre for Biotechnology Information
1 IN 4 PEOPLE WILL SUFFER MENTAL HEALTH DISORDERS
25% of adults in the world will be affected by mental or neurological disorders at some point in their lives
Source: World Health Organisation
ACN: 651 290 729
Address: Suite 301, 10 Bridge St, Sydney NSW 2000 Australia